Karthik Radhakrishnan Acquires 1,550 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Karthik Radhakrishnan purchased 1,550 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Monopar Therapeutics Trading Up 0.4 %

MNPR opened at $14.63 on Friday. The stock has a fifty day moving average price of $6.17 and a 200 day moving average price of $4.34. Monopar Therapeutics Inc. has a 1 year low of $1.37 and a 1 year high of $38.50. The stock has a market cap of $57.93 million, a price-to-earnings ratio of -6.36 and a beta of 1.26.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, sell-side analysts forecast that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MNPR has been the subject of a number of research analyst reports. HC Wainwright increased their target price on Monopar Therapeutics from $2.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $50.00 price target for the company.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.